The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Current Trends in Pharmacology and Clinical Trials>2019>2>1
Abstract
Complementary medicines are accepting world-wide and are used extensively due to its safe and non-toxic nature. The aim of the study was to evaluate the immunomodulatory potential of the Biofield Energy Treated (known as The Trivedi Effect®) novel proprietary formulation and Biofield Energy Treatment per se on male rats. The formulation was divided into two parts one part was defined as the untreated test formulation while the other part was treated with the Biofield Energy by Mahendra Kumar Trivedi and denoted as the Biofield Energy Treated test formulation. Experimental groups (G) included G1 with normal control G2 with disease control G3 with the treatment of levamisole (positive control) G4 with untreated test formulation G5 received Biofield Treated test formulation G6 consisted of Biofield Energy Treatment per se to animals (-15 days) G7 received Biofield Treated test formulation from day -15 G8 has received Biofield Energy Treatment per se to animals along with Biofield Treated test formulation from day -15 and G9 received Biofield Energy Treatment per se to animals with the untreated test formulation. The results showed that primary antibody titer value was significantly increased by 60% 63.33% 33.33% and 20% in the G6 G7 G8 and G9 groups respectively compared with the G2. However secondary antibody titer values were significantly increased by 50% 37.5% 37.5% and 12.5% in the G6 G7 G8 and G9 groups respectively compared with the G2. Delayed type hypersensitivity (DTH) reaction showed significant increase level of rat paw volume by 86.36% 30.68% and 14.77% in the G5 G6 and G7 groups respectively compared with the G2. Additionally the platelet count was significantly increased by 11.96% in G6 compared to G2. The level of uric acid was significantly reduced by 64.29% in G7 compared to G2. Further levels of calcium and phosphorous were significantly increased by 19.16% and 14.92% respectively in the G9 compared to the G2. Moreover the level of magnesium was significantly increased by 13.11% and 10.66% in G4 and G9 groups respectively compared to G2. Overall data suggests that the Biofield Treatment per se (The Trivedi Effect®) and Biofield Treated test formulation have shown significant immunomodulatory action as compared with the untreated product and unblessed rats. Therefore the Biofield Treatment could be utilised against various immuno-related disorders such as neutropenia asplenia trauma sickle cell anemia multiple myeloma chronic lymphoid leukemia stress aging etc.